Natera (NASDAQ:NTRA) Insider Sells 3,000 Shares

Key Points

• Natera insider Solomon Moshkevich sold 3,000 shares at an average price of $320.73, generating $962,190. The sale was conducted under a Rule 10b5-1 plan to cover tax withholding from vested equity awards, reducing his holdings by 2.33% to 126,019 shares.
• Natera shares traded at $327.67, near their 52-week high of $343.18, with a market capitalization of approximately $47.23 billion. The stock’s 50-day and 200-day moving averages were $291.29 and $237.00, respectively.
• The company reported quarterly revenue of $752.75 million, up 37.7% year over year and above analyst expectations, while its adjusted loss of $0.47 per share beat estimates. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $319.38.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $320.73, for a total value of $962,190.00. Following the completion of the transaction, the insider owned 126,019 shares of the company's stock, valued at approximately $40,418,073.87. This represents a 2.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80.
• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The shares were sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $272.90, for a total transaction of $818,700.00.

Natera Price Performance

Natera stock traded up $2.50 during midday trading on Thursday, hitting $327.67. 708,176 shares of the stock were exchanged, compared to its average volume of 1,439,570. Natera, Inc. has a 1 year low of $157.43 and a 1 year high of $343.18. The firm has a market cap of $47.23 billion, a P/E ratio of -240.93 and a beta of 1.54. The company has a 50 day moving average price of $291.29 and a two-hundred day moving average price of $237.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm's revenue for the quarter was up 37.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.74) EPS. As a group, analysts predict that Natera, Inc. will post -1.02 EPS for the current year.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Natera in the second quarter valued at approximately $2,962,770,000. K.J. Harrison & Partners Inc acquired a new stake in shares of Natera during the 2nd quarter worth approximately $5,117,000. Abbot Financial Management Inc. bought a new stake in shares of Natera in the 2nd quarter worth approximately $1,537,000. Eagle Health Investments LP bought a new stake in shares of Natera in the 2nd quarter worth approximately $4,302,000. Finally, Fifth Third Bancorp boosted its position in Natera by 3,373.1% during the 1st quarter. Fifth Third Bancorp now owns 11,253 shares of the medical research company's stock valued at $2,251,000 after purchasing an additional 10,929 shares during the period. 99.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on NTRA shares. Weiss Ratings restated a "sell (d-)" rating on shares of Natera in a research note on Friday, July 17th. BTIG Research upped their target price on Natera from $290.00 to $320.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Barclays reiterated an "overweight" rating and set a $340.00 target price on shares of Natera in a research note on Friday, August 7th. Evercore reissued an "outperform" rating and set a $300.00 price target on shares of Natera in a research report on Monday, July 6th. Finally, UBS Group set a $260.00 price target on shares of Natera in a research note on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus price target of $319.38.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source